Valuation: Check-Cap Ltd.

Market Cap 8.02M 7.04M 6.55M 6.01M 11.29M 772M 11.46M 77.76M 30.38M 380M 30.1M 29.45M 1.31B P/E 2024
-0.23x
P/E 2025 2.44x
Enterprise Value 7.81M 6.86M 6.38M 5.86M 11M 753M 11.17M 75.79M 29.61M 370M 29.33M 28.7M 1.28B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
62.52%
Yield 2024 *
-
Yield 2025 -
1 day-5.98%
1 week+10.00%
Current month-12.00%
1 month-14.73%
3 months-28.10%
6 months-26.17%
Current year-32.10%
1 week 0.95
Extreme 0.95
1.19
1 month 0.95
Extreme 0.95
1.29
Current year 0.95
Extreme 0.95
3.92
1 year 0.59
Extreme 0.593
3.92
3 years 0.56
Extreme 0.56
4.62
5 years 0.56
Extreme 0.56
26.2
10 years 0.56
Extreme 0.56
820.8
Manager TitleAgeSince
Chief Executive Officer 45 17/07/2024
Director of Finance/CFO 51 06/04/2025
Human Resources Officer - 01/01/2009
Director TitleAgeSince
Director/Board Member 53 25/01/2024
Chairman 45 25/01/2024
Director/Board Member 54 25/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
-5.98%+10.00%+46.86%-62.33% 8.02M
+0.95%-.--%+115.11%+11.80% 20.03B
-2.19%-4.26%+139.97%+105.56% 4.52B
-0.18%-2.84%+108.91%+185.51% 3.56B
-2.73%-0.20%+51.67%-32.29% 2.23B
-0.90%+1.56%-30.96%-37.12% 2.07B
-1.25%-6.52%+189.25%+256.77% 1.92B
-4.11%-6.63%+149.45%-45.83% 997M
-0.54%-4.03%-7.28%+32.69% 855M
-3.59%-6.57%-43.37%-17.58% 479M
Average -2.05%-1.26%+71.96%+39.72% 3.67B
Weighted average by Cap. -0.22%-1.33%+105.35%+46.14%

Financials

2024 2025
Net sales - -
Net income -25.15M -22.09M -20.54M -18.85M -35.42M -2.42B -35.96M -244M -95.3M -1.19B -94.41M -92.37M -4.12B 4.14M 3.64M 3.38M 3.1M 5.83M 399M 5.92M 40.15M 15.69M 196M 15.54M 15.21M 678M
Net Debt -129K -113K -105K -96.69K -182K -12.42M -184K -1.25M -489K -6.11M -484K -474K -21.12M -203K -178K -166K -152K -286K -19.55M -290K -1.97M -769K -9.61M -762K -746K -33.23M
Logo Check-Cap Ltd.
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. Its capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps and other structural abnormalities. C-Scan is a non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Employees
85
Date Price Change Volume
24/07/26 USD 1.100 -5.98% 15,878
23/07/26 USD 1.170 +15.84% 106,622
22/07/26 USD 1.010 -1.46% 7,138
21/07/26 USD 1.025 +7.89% 24,477
20/07/26 USD 0.9500 -5.00% 15,397
  1. Stock Market
  2. Stocks
  3. MBAI Stock